Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 5/20 | 0.73 |
| ▸ | VHL | P40337 | 8/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13442123 | 0.91 | P4HTM (0.72) | P4HTMVHLLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL8183323 | 0.91 | VHL (0.77) | P4HTMVHLNAMPT | |
| SCHEMBL8194527 | 0.90 | P4HTM (0.73) | P4HTMVHLLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL8195975 | 0.90 | P4HTM (0.73) | P4HTMVHLSMN1; SMN2L3MBTL1NAMPT | |
| SCHEMBL13408254 | 0.90 | P4HTM (0.70) | P4HTMVHLLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL13408226 | 0.88 | P4HTM (0.81) | P4HTMVHLF3 | |
| SCHEMBL3616925 | 0.88 | P4HTM (0.70) | P4HTMVHLF3 | |
| SCHEMBL13408256 | 0.87 | VHL (0.72) | P4HTMVHLNAMPT | |
| SCHEMBL13408249 | 0.87 | P4HTM (0.79) | P4HTMVHLNAMPTNPC1 | |
| SCHEMBL13408268 | 0.86 | VHL (0.74) | P4HTMVHLNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097404-B1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008067874-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | DCK, THPO, QDPR | P4HTM 412/4885VHL 25/4885LMNA 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.